---
title: "letter hiv prep"
year: 2024
month: 04
journal: "American Family Physician"
volume: "109-110"
issue: "04"
pages: ""
doi: ""
pmid: ""
source: "PDF Extraction"
pdf_available: true
original_pdf: "2024-04-letter-hiv-prep.pdf"
extracted_date: "2025-08-10"
keywords: []
evidence_level: ""
clinical_significance: ""
---

# letter hiv prep

                                               Letters to the Editor
Considerations for Implementing Cabotegravir                                         The Clinician Consultation Center PrEPline (855-488-
(Apretude) as PrEP for HIV Infection                                              7737) is available on weekdays to help with ambiguous
                                                                                  test results and provide recommendations for people who
To the Editor: Drs. El-Haddad and Erlich review an important                      may have acquired HIV infection while taking PrEP. We
new option for preventing HIV infection.1 Intramuscular cabo-                     recommend obtaining integrase strand transfer inhibi-
tegravir (Apretude) is much more effective than daily oral teno-                  tor genotype resistance testing for patients confirmed to
fovir disoproxil fumarate/emtricitabine (Truvada) at preventing                   have acquired HIV infection while taking cabotegravir;
HIV infection.2 As family physicians and HIV specialists, we are                  if antiretroviral therapy is initiated before receiving the
excited about this option but remain wary of its potential risks.                 results of resistance testing, the regimen should include
One of the more serious risks is long-acting early viral inhibition               darunavir (Prezista; a protease inhibitor) boosted with
syndrome, which can occur in people who acquire HIV infection                     ritonavir or cobicistat.5
despite appropriate use of intramuscular cabotegravir.3                           Hannah Zimmerman, MD, AAHIVS
   Long-acting early viral inhibition syndrome presents with                      Pittsburgh, Penn.
minimal symptoms, conflicting serology results that can revert to                 hannahrzimm@gmail.com

negative, and low or suppressed viral loads. These mild symptoms                  Allison Vogl, MD, AAHIVS
and ambiguous laboratory findings can culminate in months-                        McKeesport, Penn.
long delays in diagnosis and development of resistance to inte-
                                                                                  Author disclosure: No relevant financial relationships.
grase strand transfer inhibitor medications.3 This is concerning
because the integrase strand transfer inhibitor drug class is a first-            References
line treatment of HIV infection.4 Most concerning is that long-                    1. El-Haddad A, Erlich D. Cabotegravir (Apretude) for pre-
acting early viral inhibition syndrome can be found in people                         exposure prophylaxis for HIV type 1 infection. Am Fam Physician.
receiving on-time injections with adequate serum concentration                        2023;107(5):545-546.

levels of cabotegravir. Prescribers must be aware of this potential                2. Landovitz RJ, Donnell D, Clement ME, et al.; HPTN 083 Study Team.
                                                                                      Cabotegravir for HIV prevention in cisgender men and transgender
risk and adhere to the monitoring recommendations.                                    women. N Engl J Med. 2021;385(7):595-608.
   Awareness of long-acting early viral inhibition syndrome                        3. HIV Prevention Trials Network. Eshleman S. HIV infections in the set-
is vital to understanding the importance of the Centers for                           ting of long-acting early viral inhibition: the LEVI syndrome. June 7,
                                                                                      2022. Accessed December 10, 2023. https://www.hptn.org/sites/
Disease Control and Prevention recommendation to mon-                                 default/files/inline-files/TUES_14_Susan%20Eshleman_Lab%20Ple-
itor patients receiving intramuscular cabotegravir for pre-                           nary.pdf
exposure prophylaxis (PrEP) for HIV every 2 months (i.e.,                          4. Clinical Info HIV.gov. Guidelines for the use of antiretroviral agents
with each administration) using an antigen-antibody assay                             in adults and adolescents with HIV. Updated December 6, 2023.
                                                                                      Accessed December 10, 2023. https://clinicalinfo.hiv.gov/en/
and the more sensitive HIV-1 RNA assay.5 The sensitivity of                           guidelines/adult-and-adolescent-arv
the RNA assay allows for earlier detection of infection. It is                     5. Centers for Disease Control and Prevention. US Public Health Service.
also important to counsel patients on the cabotegravir “tail,”                        Preexposure prophylaxis for the prevention of HIV infection in the
which is the long and highly variable time when cabotegravir                          United States—2021 update. Accessed December 10, 2023. https://
                                                                                      www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2021.pdf
is detectable after discontinuation but below the level of pro-
tection. For 12 months after discontinuation, patients should
continue RNA testing for HIV every 3 months. If patients                            Editor’s Note: This letter was sent to the authors of
                                                                                    “Cabotegravir (Apretude) for Pre-exposure Prophylaxis for
have an ongoing indication for PrEP, oral cabotegravir PrEP                         HIV Type 1 Infection,” who declined to reply.
with tenofovir disoproxil fumarate/emtricitabine or tenofo-
vir alafenamide/emtricitabine (Descovy) should be recom-
mended to decrease the risk of acquiring HIV infection.5
                                                                                  Longer Menstrual Cycle and Infertility Evaluation

  Email letter submissions to afplet@aafp.org. Letters should                     To the Editor: In the article written by Dr. Phillips and
  be fewer than 400 words and limited to six references,                          colleagues, they describe a suggested workup for women
  one table or figure, and three authors. Letters submitted                       suspected of having anovulation.1 The article recommends
  for publication in AFP must not be submitted to any other
                                                                                  that clinicians obtain a day-21 progesterone level, and for
  publication. Letters may be edited to meet style and space
  requirements.                                                                   levels less than 3 ng per mL (9.54 nmol per L), conclude that
  This series is coordinated by Kenny Lin, MD, MPH, deputy
                                                                                  ovulation has not occurred. This method leaves out a group
  editor.                                                                         of people with a longer menstrual cycle. If a woman has a
                                                                                  35-day menstrual cycle, she may not ovulate until day 21 or 22;
                                                                                                                                                                    ▲




296  American
Downloaded       Family
            from the      Physician
                     American   Family Physician website at www.aafp.org/afp.           © 2024 American Academy ofVolume
                                                                                 Copyright
                                                                   www.aafp.org/afp                                       Family Physicians.
                                                                                                                                  109, NumberFor the
                                                                                                                                                  4 private,
                                                                                                                                                   ◆ April non-
                                                                                                                                                             2024
commercial use of one individual user of the website. All other rights reserved. Contact copyrights@aafp.org for copyright questions and/or permission requests.
                                                        LETTERS TO THE EDITOR


therefore, a day-21 progesterone level would be falsely low.                   The sentence, “However, evaluation of cervical mucus is
The algorithm should recommend a midluteal progester-                       no longer routinely used in infertility evaluation” is from
one level that would allow clinicians to discuss cycle spe-                 information provided in reference 10 and not 11, as incor-
cifics with their patients and determine which day would                    rectly cited in the article. The article has been corrected
be the most accurate time to obtain a progesterone level.                   online. We did not intend to suggest that cervical mucus
The American Society for Reproductive Medicine states,                      screening cannot be used for certain patients; however, rou-
“Given the range of normal variation in ovulatory cycles,                   tine postcoital cervical mucus testing is not recommended by
a serum progesterone measurement generally should be                        the American Society for Reproductive Medicine in the initial
obtained approximately 1 week before the expected onset                     workup of infertility.1
of the next menses, rather than on any one specific cycle                   Kiwita Phillips, MD, FACOG
day (e.g., cycle-day 21).”2                                                 Atlanta, Ga.
   The article also states that the American College of                     kphillips@msm.edu

Obstetricians and Gynecologists no longer recommends                        Raimot Olanrewaju, MD, FACOG
the examination of cervical mucus in infertility eval-                      Atlanta, Ga.
uation. Upon review of the cited reference, I could not
                                                                            Folashade Omole, MBChB, FAAFP
find any such recommendation. 3 On the contrary, the                        Atlanta, Ga.
American Society for Reproductive Medicine states that
cervical fluid tracking is an inexpensive method with                       Author disclosure: No relevant financial relationships.
moderate-quality evidence for increasing the likelihood                     Reference
of achieving pregnancy: “A retrospective cohort study
                                                                             1. Practice Committee of the American Society for Reproductive Medi-
involving 1,681 cycles observed that pregnancy rates                            cine. Fertility evaluation of infertile women: a committee opinion. Fertil
were highest (approximately 38%) when intercourse                               Steril. 2021;116(5):1255-1265.
occurred on the day of peak mucus (day 0) and apprecia-
bly lower (approximately 15% to 20%) on the day before
or after the peak.”4                                                        Airflow Reversibility in Patients With Asthma
   During a time when many patients feel a loss of con-
trol and lack of understanding, we can tailor infertility                   To the Editor: The article by Zeller and colleagues dis-
care and empower patients to understand more about                          cusses how to distinguish asthma from chronic obstruc-
their bodies.                                                               tive pulmonary disease (COPD).1 This distinction is
Anne Keenan, MD                                                             important because the treatments for the two diseases
Minneapolis, Minn.                                                          differ. The authors state, “Asthma is diagnosed if airway
hors0097@umn.edu                                                            obstruction on spirometry is reversible (greater than
Author disclosure: No relevant financial relationships.                     12% and greater than 200 mL improvement in FEV1
                                                                            [forced expiratory volume in 1 second]) with adminis-
References                                                                  tration of bronchodilators.… COPD is diagnosed if air-
 1. Phillips K, Olanrewaju RA, Omole F. Infertility: evaluation and man-    way obstruction … on spirometry is not reversible with
    agement. Am Fam Physician. 2023;107(6):623-630.                         bronchodilators.”
2. Practice Committee of the American Society for Reproductive Medi-           However, studies have shown reversibility in a signifi-
   cine. Diagnostic evaluation of the infertile female: a committee opin-
   ion. Fertil Steril. 2015;103(6):e44-e50.                                 cant proportion of patients with COPD. In the UPLIFT
3. ACOG Committee Opinion 762: Prepregnancy counseling. Obstet              trial of patients with COPD, 54% of patients had bron-
   Gynecol. 2019;133(1):e78-e89.                                            chodilator reversibility based on the American Thoracic
4. Practice Committee of the American Society for Reproductive Med-         Society criteria of FEV1 improvement of 12% or greater
   icine and the Practice Committee of the Society for Reproductive
   Endocrinology and Infertility. Optimizing natural fertility: a commit-
                                                                            and 200 mL or greater, and 73% of patients had revers-
   tee opinion. Fertil Steril. 2022;117(1):53-63.                           ibility when using the sole criteria of 12% or greater
                                                                            improvement in FEV1.2 A comprehensive review of COPD
                                                                            reversibility in multiple studies concluded that “… many
In Reply: This article was intended to serve only as a frame-               patients with COPD do indeed exhibit bronchodilator
work for the infertility workup. We agree that a patient with               reversibility and that reversibility testing is not a reliable
a longer menstrual cycle may have spuriously low progester-                 measure to differentiate between asthma and COPD.”3
one levels at day 21. There are always patient-specific char-                  The European Respiratory Society/American Thoracic
acteristics for which few algorithms can adequately account.                Society definition of reversibility was recently revised to
We advise that the recommendations be adjusted as needed                    greater than 10% of the predicted value in FEV1 or forced
to address specific situations.                                             vital capacity.4 Using this updated definition would lead

298 American Family Physician                                www.aafp.org/afp                                   Volume 109, Number 4 ◆ April 2024
                                                      LETTERS TO THE EDITOR


to a greater proportion of people with COPD being clas-                       nosis, management, and prevention of chronic obstructive pulmonary
                                                                              disease (2023 report). Accessed April 11, 2023. https://goldcopd.org/
sified as having bronchodilator reversibility compared                        wp-content/uploads/2023/03/GOLD-2023-ver-1.3-17Feb2023_WMV.
with the previous American Thoracic Society criteria of                       pdf
12% or greater.                                                            6. Global Initiative for Asthma. Global Strategy for Asthma Management
   The 2023 GOLD report states, “… assessing the degree of                    and Prevention. Updated 2022. Accessed April 16, 2023. https://ginas-
                                                                              thma.org/wp-content/uploads/2022/07/GINA-Main-Report-2022-
reversibility of airflow obstruction … to inform therapeutic                  FINAL-22-07-01-WMS.pdf
decisions is no longer recommended … and has not been
shown to differentiate the diagnosis [of COPD] from asthma,                In Reply: We appreciate the opportunity to respond
or to predict the response to long-term treatment with bron-               to this letter. Our article does not address therapy for
chodilators or corticosteroids.”5                                          asthma and COPD, but rather the diagnosis of the two
   The critical difference between COPD and asthma is that                 disease entities and distinguishing between them.
COPD is characterized by airflow limitation that is not fully                We agree that the critical difference between COPD
reversible, whereas for most people with asthma, airflow is                and asthma is that COPD is characterized by airflow
variable and reverses to near normal.5,6                                   limitation that is not fully reversible with bronchodi-
Neil Skolnik, MD                                                           lators. In contrast, asthma is characterized by airflow
Jenkintown, Pa.                                                            limitation that is variable and reversible to near normal
nskolnik@yahoo.com                                                         with bronchodilators.
Donald A. Mahler, MD                                                         As briefly discussed in our article, robust literature
Hanover, N.H.                                                              has developed around the clinical reality of coexisting
                                                                           asthma and COPD.1-4 The natural history of asthma
Barbara P. Yawn, MD, MSc, FAAFP
Minneapolis, Minn.
                                                                           is to progress to fixed obstruction over time. 5 Some
                                                                           have labeled the coexistence of the two disease entities
Author disclosures: Dr. Skolnik reports serving as a speaker,              “asthma-COPD overlap syndrome,” and for a time, it
consultant, or advisory board member for Abbot, AstraZen-                  appeared that this might become a separate diagnosis.
eca, Bayer, Boehringer Ingelheim, Boehringer Ingelheim/Lilly,
Genentech, GSK, Heartland, Idorsia, Lilly, Merck, Novartis, Novo           However, it is now standard clinical practice to diagnose
Nordisk, Sanofi, Sanofi Pasteur, and Teva,
and reports receiving research support
from AstraZeneca, Bayer, GSK, Novo Nor-           FIGURE 1
disk, and Sanofi.
Dr. Mahler reports serving as a speaker,             Asthma
consultant, or advisory board member for
AstraZeneca, Boehringer Ingelheim, GSK,
Theravance Biopharma, Verona Pharma,
and Viatris, and receives royalties from
Johns Hopkins University Press.
                                                                                                                                   Emphysema
Dr. Yawn reports serving as a speaker,
consultant, or advisory board member for
AstraZeneca, Boehringer Ingelheim, GSK,
Sunovion, and Teva.
                                                                                             Overlap
References                                                                                  syndrome

 1. Zeller TA, Beben K, Walker S. Distinguish-
    ing asthma and COPD in primary care:                                                               Chronic
    a case-based approach. Am Fam Physician.                                                          obstructive
    2023;107(3):247-252.                                                                              pulmonary
2. Tashkin DP, Celli B, Decramer M, et al. Bron-                                                       disease
   chodilator responsiveness in patients with
   COPD. Eur Respir J. 2008;31(4):742-750.
3. Hanania NA, Celli BR, Donohue JF, et al.                    Chronic
   Bronchodilator reversibility in COPD. Chest.               bronchitis
   2011;140(4):1055-1063.
4. Stanojevic S, Kaminsky DA, Miller MR, et al.
                                                     Obstructive Lung Disease Venn Diagram
   ERS/ATS technical standard on interpretive
   strategies for routine lung function tests. Eur   Adapted with permission from Soriano JB, Davis KJ, Coleman B, et al. The proportional Venn
   Respir J. 2022;60(1):2101499.                     diagram of obstructive lung disease: two approximations from the United States and the
5. Global Initiative for Chronic Obstructive         United Kingdom. Chest. 2003;124(2):475.
   Lung Disease. Global strategy for the diag-


April 2024 ◆ Volume 109, Number 4                          www.aafp.org/afp                                  American Family Physician 299
                                            LETTERS TO THE EDITOR


both asthma and COPD if the patient meets spirome-          References
try criteria for both conditions. Distinguishing between     1. Orie NGM, Sluiter HJ, de Vries K, et al. The host factor in bronchitis.
asthma and COPD is not strictly an either/or, but some-         Bronchitis. 1961:43-59.
                                                             2. Postma DS, Kerstjens HAM, Timens W. Introduction: obstructive
times a both/and situation. A Venn diagram has been             lung diseases from conception to old age. Proc Am Thorac Soc.
useful as a visual aid (Figure 1).6 We hope this response       2009;6(8):637.
helps readers in their clinical practice, and we encour-     3. Gibson PG, Simpson JL. The overlap syndrome of asthma and
age physicians to follow widely available guidelines for        COPD: what are its features and how important is it? Thorax.
                                                                2009;64(8):728–735.
treating asthma and COPD.
                                                             4. Postma DS, Rabe KF. The asthma–COPD overlap syndrome. N Engl
T. Aaron Zeller, MD                                             J Med. 2015;373(13):1241-1249.
Greenville, S.C.                                             5. de Marco R, Pesce G, Marcon A, et al. The coexistence of asthma
tazelle@clemson.edu                                             and chronic obstructive pulmonary disease (COPD): prevalence
                                                                and risk factors in young, middle-aged and elderly people from
Kati Beben, MD                                                  the general population. PLoS One. 2013;8(5):e62985.
Greenville, S.C.                                             6. Soriano JB, Davis KJ, Coleman B, et al. The proportional Venn dia-
                                                                gram of obstructive lung disease: two approximations from the
Stephanie Walker, MD                                            United States and the United Kingdom. Chest. 2003;124(2):474-
Greenville, S.C.                                                481. ■




Family Medicine
Update
Livestream
All New Content!

       April 30–May 4




                      Register Now at
                      aafp.org/FMU




300 American Family Physician                   www.aafp.org/afp                               Volume 109, Number 4 ◆ April 2024
